✅ MDR compliance requirements (what you must have)

Most MDR programs succeed when these pillars are implemented together:

• 🧾 Quality Management System (QMS) covering lifecycle controls and regulatory compliance (Article 10).
• 📚 Technical documentation (Annex II) + PMS documentation (Annex III) maintained and kept current.
• 🧑‍⚕️ Clinical evaluation and, where applicable, PMCF planning and outputs (Article 61 + Annex XIV).
• 👤 PRRC (Person Responsible for Regulatory Compliance) role defined and resourced (Article 15).
• 🏷️ UDI and traceability implemented to MDR timelines.
• 🔁 PMS + vigilance processes to detect, trend, report, and correct issues (Articles 83+ and vigilance section).

👥 Who must comply (economic operators)

MDR assigns responsibilities across the supply chain: manufacturer, authorized representative (for non-EU manufacturers), importer, and distributor—each with defined verification, recordkeeping, complaint handling, and cooperation duties.

🧭 What a company should do to comply (detailed, audit-ready roadmap)

1) 🧩 Define intended purpose and confirm classification (Annex VIII)

Classification drives conformity assessment route, notified body involvement, and post-market obligations.

Do

• Lock intended purpose, target population, user profile, and clinical/performance claims.
• Document classification rationale per device family/variant and keep it under change control.

Deliver

• Intended purpose & claims statement (label/IFU aligned)
• Classification rationale memo + device family mapping

2) 🧾 Implement MDR-ready QMS (Article 10)

MDR expects a QMS that controls compliance and operations across the device lifecycle.

Do

• Establish document control, training/competence, design controls, supplier controls, production controls, change control, CAPA, internal audits, and management review.
• Integrate risk management, clinical evaluation, and PMS into one closed-loop system.

Deliver

• MDR-aligned SOP set + records/templates
• Audit program and CAPA workflow, role/ownership map (incl. PRRC duties)

3) 🛡️ Prove Annex I GSPR conformity (requirements-to-evidence mapping)

Annex I “General Safety and Performance Requirements” (GSPR) is the backbone of your technical file.

Do

• Build a GSPR checklist and map each applicable requirement to evidence.
• Link risks → controls → verification/validation → labeling/IFU → clinical evidence.

Deliver

• GSPR checklist (traceable and reviewable)
• Risk management file + benefit–risk justification

4) 🧪 Materials & substances: manage Annex I Section 10.4 obligations

If certain hazardous substances are present above defined thresholds, MDR requires additional justification and information controls (including documentation and, where required, labeling/IFU content).

Do

• Build a material/substance inventory (BOM, coatings, additives, residues, supplier declarations).
• Assess applicability and thresholds; document justification and risk communication governance.

Deliver

• Supplier declaration package + substance assessment records
• Controlled labeling/IFU inputs for residual risk communication (where applicable)

5) 📚 Build MDR technical documentation (Annex II) + PMS documentation (Annex III)

Technical documentation must be structured, complete, and maintained through change control.

Include (typical core set)

• Device description/specs, variants, intended purpose
• Design & manufacturing information
• GSPR checklist + risk management summary
• Verification/validation evidence (pre-clinical + clinical)
• PMS plan and PMS outputs structure

Deliver

• Annex II/III index and evidence library (searchable, versioned)
• Traceability matrix (claims ↔ risks ↔ tests ↔ clinical ↔ PMS)

6) 🧑‍⚕️ Clinical evaluation and PMCF (Article 61 + Annex XIV)

Clinical evaluation is required and must be maintained throughout the device lifecycle; PMCF applies where needed to proactively gather clinical data.

Do

• Create CEP/CER (plan/report), define evidence strategy (including equivalence rationale if used), and maintain updates driven by PMS.
• Implement PMCF planning and periodic evaluation where applicable.

Deliver

• CEP/CER package + PMCF plan/evaluation (as applicable)
• Clinical evidence gap analysis + remediation plan

7) 🏛️ Conformity assessment route and notified body readiness

For many device classes, a notified body is required. MDR readiness depends on both documentation quality and system maturity.

Do

• Select conformity assessment pathway; prepare audit evidence; establish structured responses for findings.
• Implement “change impact assessment” (design/material/software changes ↔ regulatory impact).

Deliver

• Conformity assessment plan + audit readiness pack
• Change impact assessment workflow + records

8) 🏷️ UDI + EUDAMED readiness (critical dates)

UDI carrier deadlines (labels)

EU UDI carrier placement deadlines (MDR) include:

• Implantable & Class III: 26 May 2021
• Class IIa & IIb: 26 May 2023
• Class I: 26 May 2025

EUDAMED mandatory use date (first 4 modules)

The European Commission states the first four EUDAMED modules become mandatory from 28 May 2026 (Actor registration; UDI/Devices registration; Notified Bodies & Certificates; Market Surveillance).

Do

• Establish master data governance (Basic UDI-DI, UDI-DI/UDI-PI, label control, certificate links).
• Assign ownership and SOPs for submissions and evidence retention.

Deliver

• UDI master data model + label governance procedures
• EUDAMED readiness checklist aligned to the mandatory modules

9) 🔁 Post-Market Surveillance (PMS), PSUR, and vigilance (continuous compliance)

MDR requires an active PMS system integrated into the QMS, producing defined outputs (e.g., PMS report / PSUR depending on class) and supporting vigilance reporting and corrective actions.

Do

• Implement PMS plan execution, signal detection/trending, complaint handling, and CAPA linkage.
• Keep risk management, clinical evaluation, and labeling/IFU updated based on PMS outcomes.

Deliver

• PMS plan + periodic outputs (PMS report/PSUR as applicable)
• Vigilance and FSCA workflows + escalation rules + templates

🗓️ Transitional provisions (legacy devices)

If you have “legacy” devices, MDR transitional provisions may apply, and Regulation (EU) 2023/607 updated transition mechanics and removed the “sell-off” deadlines (subject to conditions).

🧰 What this MDR compliance service delivers

• 🧭 Scope + intended purpose + classification rationale (Annex VIII)
• 🧾 QMS readiness program aligned to Article 10 (gap assessment → remediation → audit support)
• 📚 Annex II/III technical documentation build/remediation and evidence traceability
• 🧑‍⚕️ Clinical evaluation and PMCF program alignment (Article 61 + Annex XIV)
• 🧪 Materials/substances governance aligned to Annex I requirements (incl. Section 10.4 controls)
• 🏷️ UDI + EUDAMED readiness aligned to mandatory date (28 May 2026)
• 🔁 PMS/PSUR/vigilance system implementation with CAPA traceability

🌟 Why ComplyMarket for MDR material + compliance reporting

ComplyMarket helps MDR teams execute the hardest part consistently: materials/substances, supplier evidence, traceability, and audit-proof reporting—without spreadsheet chaos.

With ComplyMarket’s Material Compliance Management & Reporting Platform, you can:

• 🧾 Centralize BOMs, material specs, and supplier declarations to support Annex I substance controls and technical documentation evidence packs.
• 🧪 Run structured substance checks, keep justifications versioned, and govern label/IFU inputs when material compositions change.
• 📚 Link evidence (test reports, risk records, clinical files, PMS outputs) to product versions so notified body reviews and internal audits move faster.
• 🔁 Maintain end-to-end traceability from complaints/PMS signals to CAPA and impacted components/material lots.
• 🏷️ Strengthen UDI/EUDAMED data governance by keeping product master data consistent across labeling, registrations, and documentation sets.

ComplyMarket is the best-ever, integrated solution for turning MDR requirements into repeatable workflows—reducing rework, improving supplier accountability, and keeping compliance continuously under control.